-transparent.png){kind=logo}
Anaphylaxis or significant hypersensitivity reaction is one of the most catastrophic potential complications of chemotherapy. There is a 2-5% risk of hypersensitivity with paclitaxel, a commonly used chemotherapeutic agent for various cancers. Three patients, who developed hypersensitivity to paclitaxel infusion, received docetaxel without allergic reactions. Docetaxel may therefore be an alternative treatment for patients with paclitaxel hypersensitivity.
Related Publications
C Moon, and
C F Verschraegen, and
M Bevers, and
R Freedman, and
A P Kudelka, and
J J Kavanagh
October 1993,
Cancer treatment reviews,
C Moon, and
C F Verschraegen, and
M Bevers, and
R Freedman, and
A P Kudelka, and
J J Kavanagh
March 2003,
International journal of cancer,
C Moon, and
C F Verschraegen, and
M Bevers, and
R Freedman, and
A P Kudelka, and
J J Kavanagh
December 2003,
International immunopharmacology,
C Moon, and
C F Verschraegen, and
M Bevers, and
R Freedman, and
A P Kudelka, and
J J Kavanagh
January 2000,
Cancer investigation,
C Moon, and
C F Verschraegen, and
M Bevers, and
R Freedman, and
A P Kudelka, and
J J Kavanagh
April 1995,
Lung cancer (Amsterdam, Netherlands),
C Moon, and
C F Verschraegen, and
M Bevers, and
R Freedman, and
A P Kudelka, and
J J Kavanagh
July 1994,
Annals of oncology : official journal of the European Society for Medical Oncology,
C Moon, and
C F Verschraegen, and
M Bevers, and
R Freedman, and
A P Kudelka, and
J J Kavanagh
August 1995,
Bulletin du cancer,
C Moon, and
C F Verschraegen, and
M Bevers, and
R Freedman, and
A P Kudelka, and
J J Kavanagh
April 1996,
Cancer research,
C Moon, and
C F Verschraegen, and
M Bevers, and
R Freedman, and
A P Kudelka, and
J J Kavanagh
January 1994,
Journal de pharmacie de Belgique,
C Moon, and
C F Verschraegen, and
M Bevers, and
R Freedman, and
A P Kudelka, and
J J Kavanagh
November 2001,
British journal of cancer,
